
Integris Medtech IPO
- Price band
- —
- Issue size
- —
- Min. investment
- —
- GMP
- —
- —
- Subscribed
- —
- Bidding dates
- 27 Nov – 1 Dec 2026
IPO timeline
- Opens27 NovFri
- Closes1 DecTue
- Allotment2 DecWed
- RefundsTo be announced
- Demat creditTo be announced
- Listing4 DecFri
Issue details
- Price band
- —
- Issue size
- —
- Fresh issue
- Not available
- Offer for sale
- Not available
- Issue type
- Fresh capital and offer for sale
- Face value
- ₹1 per share
- Lot size
- —
- Minimum investment
- —
- Listing on
- BSE, NSE
- Exchange code
- —
This issue combines a fresh issue and an offer for sale. The amounts for each part are not available in our data; see the offer document for the split.
Grey market premium (GMP)
No grey market activity has been reported for this issue yet.
GMP is an unofficial indicator from an unregulated market. It is shown for information only and is not a prediction of the listing price or a recommendation to apply.
Subscription status
Subscription figures will appear here once bidding opens on 27 Nov 2026.
Financials
- EPS (₹)
- 5.82
- NAV (₹)
- 316.09
| Period ended | 30 Jun 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue from Operations | 485.25 | 1902.47 | 1553.38 | 1348.10 |
| Total Income | 508.93 | 1959.58 | 1582.26 | 1369.66 |
| Profit After Tax | 267.57 | 70.68 | -4.88 | -40.54 |
| Net Worth | 3889.99 | 2752.52 | 2681.02 | 2629.52 |
| Total Borrowing | 793.42 | 1729.46 | 813.10 | 556.54 |
Peer comparison
| Company | Issue size | P/E | RoNW | PAT margin | Subscribed | Listing gain |
|---|---|---|---|---|---|---|
| Integris Medtech This IPO | — | — | — | — | — | — |
| Anlon Healthcare Mainboard · listed 3 Sep 2025 | ₹121.03 Cr | 23.57 | 25.51% | 17.06% | 7.12x | +1.10% |
| Amanta Healthcare Mainboard · listed 9 Sep 2025 | ₹126 Cr | 46.59 | 10.89% | 3.86% | 82.6x | +7.14% |
| Kronox Lab Sciences Mainboard · listed 10 Jun 2024 | ₹130.15 Cr | 24.47 | 25.66% | 22.60% | 117.25x | +21.29% |
| Hexagon Nutrition Mainboard · listed 12 Jun 2026 | ₹138.87 Cr | 15.35 | 12.12% | 9.81% | 53.68x | +7.22% |
| Gaudium IVF Mainboard · listed 27 Feb 2026 | ₹165 Cr | 22.99 | 41.71% | 26.96% | 7.27x | +5.06% |
| Gujarat Kidney & Super Speciality Mainboard · listed 30 Dec 2025 | ₹250.8 Cr | 61.62 | 36.61% | 23.61% | 5.21x | +5.26% |
Peers are other recent IPOs from the same industry, closest in issue size. Ratios are as disclosed at the time of each issue. This is not the listed-peer table from the offer document.
IPO objectives
How Integris Medtech plans to use the money raised, as stated in the offer document.
- Repay or prepay borrowings of wholly-owned subsidiaries Translumina Therapeutics, Transhealth and HaleMed Medical (Rs 125.40 crore) and of step-down subsidiaries (Rs 570.99 crore)₹696.39 Cr
- General corporate purposes
About Integris Medtech
Integris Medtech Limited was formerly known as Integris Health Private Limited. It describes itself as a diversified India-based global medical products and laboratory solutions company. It develops, makes and sells medical devices and solutions across cardiovascular devices, clinical diagnostics and scientific laboratory solutions. Its products are sold in more than 65 countries as of 30 June 2025. The company runs three manufacturing facilities in Dehradun, India, and one facility each in Chennai, the Netherlands and Germany. Dehradun houses several of these plants, so output is concentrated in one Indian city. The cardiovascular business depends on nine principal raw material suppliers, and six critical materials come from single suppliers. Two segments are reported. The lab solutions segment gave Rs 12,412.48 million, or 65.24% of revenue from operations, in FY2025. The cardiovascular segment gave Rs 6,612.18 million, or 34.76%. In the three months ended 30 June 2025 the split was 66.51% and 33.49%. A large part of sales comes from outside India. Jurisdictions outside India gave 66.12% of revenue from operations in the three months ended 30 June 2025, 64.91% in FY2025, 60.40% in FY2024 and 58.88% in FY2023. The company has also grown through acquisitions, and the document says its business model has relied significantly on them. The company had 1,879 employees on a consolidated basis as of 30 June 2025, against 1,481 at the end of FY2025. Its promoters are Evercure Holdings Pte. Ltd., Medicore Holdings Pte. Ltd., Gurmit Singh Chugh and Punita Sharma. The registered office is in New Delhi and the corporate office is in Noida.
Strengths
- Revenue from operations rose from Rs 13,481.04 million in FY2023 to Rs 15,533.82 million in FY2024 and Rs 19,024.66 million in FY2025.
- Sales reach more than 65 countries, and 64.91% of FY2025 revenue came from outside India, so the business is not tied to one home market.
- Two segments share the revenue: lab solutions at 65.24% and cardiovascular at 34.76% in FY2025.
- The company makes products in six facilities across India, the Netherlands and Germany, with three of them in Dehradun.
- Net cash from operating activities grew from Rs 194.43 million in FY2023 to Rs 972.55 million in FY2024 and Rs 1,555.43 million in FY2025.
- The top 10 customers gave only 16.33% of FY2025 revenue and 12.64% in FY2024, so no single buyer dominates sales.
Risks
- The company reported a restated loss of Rs 405.41 million in FY2023 and Rs 48.84 million in FY2024. FY2025 profit was Rs 706.84 million.
- Restated profit of Rs 2,675.67 million for the three months to 30 June 2025 includes a one-time exceptional gain of Rs 2,396.23 million from a deemed disposal of investments.
- Total borrowings rose from Rs 5,565.35 million in FY2023 to Rs 17,294.58 million in FY2025. These include promissory notes of Rs 7,923.55 million.
- Fresh issue money of Rs 6,963.90 million is meant to repay borrowings of subsidiaries, and the rest, within a 25% cap, goes to unspecified general corporate purposes.
- The business has relied significantly on acquisitions, and the pro forma FY2025 revenue of Rs 23,328.12 million shows how much recent acquisitions change the picture.
- Outside India gave 66.12% of revenue in the latest period, which exposes the company to foreign regulation and currency swings.
- Employee attrition was 23.57% in FY2025 and 27.40% in FY2024, and the only KMP resigned in both years.
- Three plants sit in Dehradun, and the cardiovascular business depends on nine principal raw material suppliers, with six critical materials from single suppliers.
- Promoter Gurmit Singh Chugh, a subsidiary and a senior manager are party to a regulatory proceeding of Rs 150.91 million. It is fully paid and a closure report is awaited.
- Promoters Gurmit Singh Chugh and Punita Sharma sell shares at an average cost of Rs 31.59 each, and Evercure sells at Rs 203.43 each.
Promoters and shareholding
Evercure Holdings Pte. Ltd., Medicore Holdings Pte. Ltd., Gurmit Singh Chugh and Punita Sharma
- Promoter holding, pre-issue
- 83.24%
- Promoter holding, post-issue
- —
Registrar, lead managers and documents
Company contact
Unit 702 & 703, BPTP Capital City, Sector 94, Noida 201 301, Uttar Pradesh
+91 120 4531422
investors@integrismedtech.comDocuments
Integris Medtech IPO: common questions
1.When does the Integris Medtech IPO open and close?
The Integris Medtech IPO opens on 27 Nov 2026 and closes on 1 Dec 2026.
2.When is the Integris Medtech IPO allotment?
The basis of allotment is expected on 2 Dec 2026. Allotment status can be checked with the registrar, KFin Technologies Limited.
3.When will the Integris Medtech IPO list?
The shares are expected to list on 4 Dec 2026 on BSE, NSE.
4.Who is the lead manager of the Integris Medtech IPO?
The book running lead managers are Axis Capital, ICICI Securities, IIFL Capital Services Limited, and the registrar is KFin Technologies Limited.
5.What will the money raised in the Integris Medtech IPO be used for?
As stated in the offer document, the proceeds are for: Repay or prepay borrowings of wholly-owned subsidiaries Translumina Therapeutics, Transhealth and HaleMed Medical (Rs 125.40 crore) and of step-down subsidiaries (Rs 570.99 crore); General corporate purposes.
6.How can my company launch an IPO like Integris Medtech?
Start with an IPO readiness assessment: eligibility for the Main Board, audited financials, governance, conversion to a public limited company and an indicative valuation. Be IPO Ready advises promoters through each step, from readiness to listing day.
For business owners
Your company could be the next listing
Businesses like these raise growth capital on the public markets every week. Tell us about yours and our advisors will tell you, plainly, whether an IPO is within reach and what it would take.
- Eligibility check against NSE Emerge, BSE SME and Main Board norms
- Indicative valuation and issue size for your business
- A clear timeline from readiness to listing day
Check if your business can list
Fill in the eligibility form and get an assessment of where you stand. It takes about five minutes.
Prefer to talk? Call +91 92130 20393